Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


1. (3,5-dichloro-4-hydroxyphenyl)-(1,1-dioxo-2h-1,3-benzothiazol-3-yl)methanone
2. Fyu-981
1. 1285572-51-1
2. Fyu-981
3. Dotinurad [inn]
4. (3,5-dichloro-4-hydroxyphenyl)(1,1-dioxidobenzo[d]thiazol-3(2h)-yl)methanone
5. 305eb53128
6. (3,5-dichloro-4-hydroxyphenyl)-(1,1-dioxo-2h-1,3-benzothiazol-3-yl)methanone
7. Urece
8. Methanone, (3,5-dichloro-4-hydroxyphenyl)(1,1-dioxido-3(2h)-benzothiazolyl)-
9. Urece (tn)
10. Dotinurad (jan/inn)
11. Dotinurad [jan]
12. Dotinurad [who-dd]
13. Fyu981
14. Chembl4594446
15. Schembl10322525
16. Gtpl11389
17. Unii-305eb53128
18. Ex-a5737
19. Bdbm50561689
20. Hy-109031
21. Cs-0030545
22. D11071
23. 3-(3,5-dichloro-4-hydroxybenzoyl)-1,1-dioxo-2,3-dihydro-1,3-benzothiazole
| Molecular Weight | 358.2 g/mol |
|---|---|
| Molecular Formula | C14H9Cl2NO4S |
| XLogP3 | 2.9 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 4 |
| Rotatable Bond Count | 1 |
| Exact Mass | 356.9629343 g/mol |
| Monoisotopic Mass | 356.9629343 g/mol |
| Topological Polar Surface Area | 83.1 Ų |
| Heavy Atom Count | 22 |
| Formal Charge | 0 |
| Complexity | 538 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Uricosuric Agents
Gout suppressants that act directly on the renal tubule to increase the excretion of uric acid, thus reducing its concentrations in plasma. (See all compounds classified as Uricosuric Agents.)
Jinan Tantu Chemicals offers customized R&D services & production of small molecule APIs & pharmaceutical intermediates.
Lewens Labs transforms healthcare with innovative, sustainable, and affordable pharmaceutical solutions worldwide.


Registration Number : 230MF10137
Registrant's Address : 6-11-24 Tsudanuma, Narashino City, Chiba Prefecture
Initial Date of Registration : 2018-10-01
Latest Date of Registration :



FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Registration Number : 230MF10137
Registrant's Address : 6-11-24 Tsudanuma, Narashino City, Chiba Prefecture
Initial Date of Registration : 2018-10-01
Latest Date of Registration : 2018-10-01

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Jinan Tantu Chemicals offers customized R&D services & production of small molecule APIs & pharmaceutical intermediates.
About the Company : Jinan Tantu Chemicals Co., Ltd. operates as a Contract Development and Manufacturing Organization (CDMO) that serves pharmaceutical companies worldwide. Our core services include c...
About the Company : Established in May 2012, Shandong Loncom Pharmaceutical operates as a fully owned subsidiary of Shandong Bestcomm Pharmaceutical Co., Ltd. Situated in the Qihe Economic Development...
Lewens Labs transforms healthcare with innovative, sustainable, and affordable pharmaceutical solutions worldwide.
About the Company : Lewens Labs was established with a vision to transform the pharmaceutical industry, inspired by an award-winning engineering project that reduced the cost of Aceclofenac and earned...
About the Company : Beijing Sjar Technology Development Co., Ltd. founded in 2014, it is a high-tech enterprise which specialized in the research and development of active pharmaceutical ingredients a...

About the Company : Founded by chemists with years of working experiences in famous CRO companies in China, Excenen Pharmatech experienced in organic chemistry expecially in medicinal chemistry resear...

About the Company : Guangzhou Green Cross Pharmaceutical is a leading Chinese manufacturer of amino acid injection formulations and a full-service provider of high-end parenteral nutrition and generic...

About the Company : Shenzhen Tianyuan Pharmaceutical Technology Co., Ltd. is a manufacturer specializing in targeted anticancer drug research and is devoted to researching, manufacturing and marketing...

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
The financing round will support the advancement of Phase 3 evaluating, FYU-981 (dotinurad), a next-generation, once daily oral, URAT1 inhibitor for the treatment of gout.
Lead Product(s): Dotinurad,Allopurinol
Therapeutic Area: Rheumatology Brand Name: FYU-981
Study Phase: Phase I/ Phase IIProduct Type: Miscellaneous
Sponsor: Novo Holdings
Deal Size: $205.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing September 30, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Dotinurad,Allopurinol
Therapeutic Area : Rheumatology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Novo Holdings
Deal Size : $205.0 million
Deal Type : Series A Financing
Novo-Backed Crystalys Debuts With $205M to Tackle Gout
Details : The financing round will support the advancement of Phase 3 evaluating, FYU-981 (dotinurad), a next-generation, once daily oral, URAT1 inhibitor for the treatment of gout.
Product Name : FYU-981
Product Type : Miscellaneous
Upfront Cash : Undisclosed
September 30, 2025

Details:
Dotinurad is a Other Small Molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Gout.
Lead Product(s): Dotinurad,Inapplicable
Therapeutic Area: Rheumatology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 28, 2025

Lead Product(s) : Dotinurad,Inapplicable
Therapeutic Area : Rheumatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of Dotinurad Versus Allopurinol in Participants with Gout
Details : Dotinurad is a Other Small Molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Gout.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 28, 2025

Details:
Dotinurad is a Other Small Molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Gout.
Lead Product(s): Dotinurad,Inapplicable
Therapeutic Area: Rheumatology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 28, 2025

Lead Product(s) : Dotinurad,Inapplicable
Therapeutic Area : Rheumatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of Dotinurad Versus Allopurinol in Tophaceous Gout
Details : Dotinurad is a Other Small Molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Gout.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 28, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Dotinurad, a novel urate transporter (URAT1) inhibitor for gout with potential to address other conditions associated with hyperuricemia such as chronic kidney disease.
Lead Product(s): Dotinurad,Inapplicable
Therapeutic Area: Rheumatology Brand Name: Urece
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 08, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Dotinurad,Inapplicable
Therapeutic Area : Rheumatology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Thailand Approves New Therapeutic Medicine for Gout and Hyperuricemia
Details : Dotinurad, a novel urate transporter (URAT1) inhibitor for gout with potential to address other conditions associated with hyperuricemia such as chronic kidney disease.
Product Name : Urece
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 08, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Dontinurad is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Gout.
Lead Product(s): Dontinurad,Dotinurad,Allopurinol
Therapeutic Area: Rheumatology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 28, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Dontinurad,Dotinurad,Allopurinol
Therapeutic Area : Rheumatology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Open Label PK, PD and DDI of Dotinurad and Allopurinol in Gout Patients with Hyperuricemia
Details : Dontinurad is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Gout.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 28, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Dotinurad, a novel urate transporter (URAT1) inhibitor for gout with potential to address other conditions associated with hyperuricemia such as chronic kidney disease.
Lead Product(s): Dotinurad,Inapplicable
Therapeutic Area: Rheumatology Brand Name: Urece
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Fortress Biotech
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 29, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Dotinurad,Inapplicable
Therapeutic Area : Rheumatology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Fortress Biotech
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Dotinurad, a novel urate transporter (URAT1) inhibitor for gout with potential to address other conditions associated with hyperuricemia such as chronic kidney disease.
Product Name : Urece
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 29, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Urece (dotinurad) is a potential best-in-class urate transporter inhibitor that is currently in Phase 1 clinical trial and being developed for the treatment of gout. It can lower blood uric acid levels by selectively inhibiting URAT1 and uric acid reabsorption in the kidneys.
Lead Product(s): Dotinurad,Inapplicable
Therapeutic Area: Rheumatology Brand Name: Urece
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Urica Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement December 14, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Dotinurad,Inapplicable
Therapeutic Area : Rheumatology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Urica Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Urece (dotinurad) is a potential best-in-class urate transporter inhibitor that is currently in Phase 1 clinical trial and being developed for the treatment of gout. It can lower blood uric acid levels by selectively inhibiting URAT1 and uric acid reabso...
Product Name : Urece
Product Type : Miscellaneous
Upfront Cash : Undisclosed
December 14, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Dotinurad (URECE® tablet) was approved in Japan in 2020 as a once-daily oral therapy for gout and hyperuricemia. Dotinurad was efficacious and well-tolerated in more than 500 Japanese patients treated for up to 58 weeks in Phase 3 clinical trials.
Lead Product(s): Dotinurad,Inapplicable
Therapeutic Area: Rheumatology Brand Name: Urece
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Fuji Yakuhin
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 31, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Dotinurad,Inapplicable
Therapeutic Area : Rheumatology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Fuji Yakuhin
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Dotinurad (URECE® tablet) was approved in Japan in 2020 as a once-daily oral therapy for gout and hyperuricemia. Dotinurad was efficacious and well-tolerated in more than 500 Japanese patients treated for up to 58 weeks in Phase 3 clinical trials.
Product Name : Urece
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 31, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Dotinurad is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): Dotinurad,Inapplicable
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 14, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Dotinurad,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Single and Multiple Dose Study of Dotinurad in Chinese Healthy Participants
Details : Dotinurad is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 14, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Dotinurad is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Gout.
Lead Product(s): Dotinurad,Inapplicable
Therapeutic Area: Rheumatology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 16, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Dotinurad,Inapplicable
Therapeutic Area : Rheumatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Dotinurad is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Gout.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 16, 2021

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
Reply
29 Sep 2025
Reply
09 Aug 2023
Reply
10 May 2023
Reply
27 Sep 2022
Reply
05 Aug 2022
Reply
13 Aug 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
ABOUT THIS PAGE
51
PharmaCompass offers a list of Dotinurad API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Dotinurad manufacturer or Dotinurad supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Dotinurad manufacturer or Dotinurad supplier.
PharmaCompass also assists you with knowing the Dotinurad API Price utilized in the formulation of products. Dotinurad API Price is not always fixed or binding as the Dotinurad Price is obtained through a variety of data sources. The Dotinurad Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Dotinurad manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Dotinurad, including repackagers and relabelers. The FDA regulates Dotinurad manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Dotinurad API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Dotinurad manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Dotinurad supplier is an individual or a company that provides Dotinurad active pharmaceutical ingredient (API) or Dotinurad finished formulations upon request. The Dotinurad suppliers may include Dotinurad API manufacturers, exporters, distributors and traders.
click here to find a list of Dotinurad suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Dotinurad Drug Master File in Japan (Dotinurad JDMF) empowers Dotinurad API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Dotinurad JDMF during the approval evaluation for pharmaceutical products. At the time of Dotinurad JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Dotinurad suppliers with JDMF on PharmaCompass.
Dotinurad Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Dotinurad GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Dotinurad GMP manufacturer or Dotinurad GMP API supplier for your needs.
A Dotinurad CoA (Certificate of Analysis) is a formal document that attests to Dotinurad's compliance with Dotinurad specifications and serves as a tool for batch-level quality control.
Dotinurad CoA mostly includes findings from lab analyses of a specific batch. For each Dotinurad CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Dotinurad may be tested according to a variety of international standards, such as European Pharmacopoeia (Dotinurad EP), Dotinurad JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Dotinurad USP).